Immatics N.V. Updates Uveal Melanoma Trial Data
Ticker: IMTX · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1809196
| Field | Detail |
|---|---|
| Company | Immatics N.V. (IMTX) |
| Form Type | 6-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, oncology, cell-therapy
TL;DR
Immatics dropped new uveal melanoma trial data for anzu-cel, 16 patients treated, looks promising.
AI Summary
On October 20, 2025, Immatics N.V. released updated Phase 1b clinical trial data for 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell therapy. The data, with a cutoff of September 24, 2025, showed that all 16 patients received a single infusion of anzu-cel at the recommended Phase 2 dose (RP2D), ranging from 1 to 10 billion cells.
Why It Matters
This update provides crucial insights into the efficacy and safety of Immatics' lead cell therapy candidate, anzu-cel, for a rare and aggressive form of cancer.
Risk Assessment
Risk Level: medium — Clinical trial data updates carry inherent risks related to efficacy, safety, and future regulatory approval.
Key Numbers
- 16 — Patients (Number of patients with metastatic uveal melanoma in the Phase 1b trial)
- 1 to 10 billion — Cells (Dose range administered per patient in the trial)
Key Players & Entities
- Immatics N.V. (company) — Registrant and developer of anzu-cel
- anzu-cel PRAME (drug) — Cell therapy being evaluated
- metastatic uveal melanoma (disease) — Indication for the clinical trial
- October 20, 2025 (date) — Date of the report filing
- September 24, 2025 (date) — Data cutoff date for the trial
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K filing provides updated data from a Phase 1b clinical trial evaluating anzu-cel PRAME cell therapy in patients with metastatic uveal melanoma.
What specific data was updated in this report?
Updated data from 16 patients with metastatic uveal melanoma who received a one-time infusion of anzu-cel at the recommended Phase 2 dose (RP2D) was provided.
What was the data cutoff date for this update?
The data cutoff date for this update was September 24, 2025.
What is the recommended Phase 2 dose (RP2D) for anzu-cel?
The recommended Phase 2 dose (RP2D) for anzu-cel is between 1 to 10 billion cells.
What type of cancer is anzu-cel being tested for in this trial?
Anzu-cel is being tested for metastatic uveal melanoma in this Phase 1b clinical trial.
Filing Stats: 949 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2025-10-20 10:30:28
Filing Documents
- dp235990_6k.htm (6-K) — 22KB
- dp235990_ex9901.htm (EX-99.1) — 31KB
- dp235990_ex9902.htm (EX-99.2) — 38KB
- dp235990_ex9903.htm (EX-99.3) — 95KB
- ex9902_001.jpg (GRAPHIC) — 433KB
- ex9902_002.jpg (GRAPHIC) — 395KB
- ex9902_003.jpg (GRAPHIC) — 155KB
- ex9902_004.jpg (GRAPHIC) — 326KB
- ex9902_005.jpg (GRAPHIC) — 271KB
- ex9902_006.jpg (GRAPHIC) — 211KB
- ex9902_007.jpg (GRAPHIC) — 409KB
- ex9902_008.jpg (GRAPHIC) — 320KB
- ex9902_009.jpg (GRAPHIC) — 183KB
- ex9902_010.jpg (GRAPHIC) — 302KB
- ex9902_011.jpg (GRAPHIC) — 438KB
- ex9902_012.jpg (GRAPHIC) — 297KB
- ex9902_013.jpg (GRAPHIC) — 257KB
- ex9902_014.jpg (GRAPHIC) — 284KB
- ex9902_015.jpg (GRAPHIC) — 254KB
- ex9902_016.jpg (GRAPHIC) — 323KB
- ex9902_017.jpg (GRAPHIC) — 279KB
- ex9902_018.jpg (GRAPHIC) — 229KB
- ex9902_020.jpg (GRAPHIC) — 152KB
- ex9902_021.jpg (GRAPHIC) — 156KB
- ex9902_022.jpg (GRAPHIC) — 370KB
- ex9902_023.jpg (GRAPHIC) — 374KB
- ex9903_001.jpg (GRAPHIC) — 295KB
- ex9903_002.jpg (GRAPHIC) — 699KB
- ex9903_003.jpg (GRAPHIC) — 380KB
- ex9903_004.jpg (GRAPHIC) — 380KB
- ex9903_005.jpg (GRAPHIC) — 334KB
- ex9903_006.jpg (GRAPHIC) — 361KB
- ex9903_007.jpg (GRAPHIC) — 344KB
- ex9903_008.jpg (GRAPHIC) — 305KB
- ex9903_009.jpg (GRAPHIC) — 163KB
- ex9903_010.jpg (GRAPHIC) — 284KB
- ex9903_011.jpg (GRAPHIC) — 459KB
- ex9903_012.jpg (GRAPHIC) — 362KB
- ex9903_013.jpg (GRAPHIC) — 376KB
- ex9903_014.jpg (GRAPHIC) — 445KB
- ex9903_015.jpg (GRAPHIC) — 318KB
- ex9903_016.jpg (GRAPHIC) — 312KB
- ex9903_017.jpg (GRAPHIC) — 260KB
- ex9903_018.jpg (GRAPHIC) — 465KB
- ex9903_019.jpg (GRAPHIC) — 295KB
- ex9903_020.jpg (GRAPHIC) — 339KB
- ex9903_021.jpg (GRAPHIC) — 376KB
- ex9903_022.jpg (GRAPHIC) — 158KB
- ex9903_023.jpg (GRAPHIC) — 370KB
- ex9903_024.jpg (GRAPHIC) — 362KB
- ex9903_025.jpg (GRAPHIC) — 302KB
- ex9903_026.jpg (GRAPHIC) — 495KB
- ex9903_027.jpg (GRAPHIC) — 361KB
- ex9903_028.jpg (GRAPHIC) — 351KB
- ex9903_029.jpg (GRAPHIC) — 345KB
- ex9903_030.jpg (GRAPHIC) — 151KB
- ex9903_031.jpg (GRAPHIC) — 313KB
- ex9903_032.jpg (GRAPHIC) — 295KB
- ex9903_033.jpg (GRAPHIC) — 321KB
- ex9903_034.jpg (GRAPHIC) — 425KB
- ex9903_035.jpg (GRAPHIC) — 343KB
- ex9903_036.jpg (GRAPHIC) — 296KB
- ex9903_037.jpg (GRAPHIC) — 151KB
- ex9903_038.jpg (GRAPHIC) — 230KB
- ex9903_039.jpg (GRAPHIC) — 270KB
- ex9903_040.jpg (GRAPHIC) — 413KB
- ex9903_041.jpg (GRAPHIC) — 358KB
- ex9903_042.jpg (GRAPHIC) — 453KB
- ex9903_043.jpg (GRAPHIC) — 223KB
- ex9903_044.jpg (GRAPHIC) — 341KB
- ex9903_045.jpg (GRAPHIC) — 294KB
- ex9903_046.jpg (GRAPHIC) — 289KB
- ex9903_047.jpg (GRAPHIC) — 353KB
- image_001.jpg (GRAPHIC) — 35KB
- image_002.jpg (GRAPHIC) — 25KB
- image_003.jpg (GRAPHIC) — 44KB
- image_004.jpg (GRAPHIC) — 4KB
- image_005.jpg (GRAPHIC) — 35KB
- image_006.jpg (GRAPHIC) — 34KB
- image_007.jpg (GRAPHIC) — 396KB
- 0000950103-25-013381.txt ( ) — 31603KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMATICS N.V. Date: October 20, 2025 By: /s/ Harpreet Singh Name: Harpreet Singh Title: Chief Executive Officer